Abivax (ABVX) Total Non-Current Liabilities (2022 - 2026)

Abivax's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $64.8 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 9.18% year-over-year to $64.8 million; the TTM figure through Mar 2026 stood at $64.8 million (down 9.18% YoY), while the FY2025 annual figure was $77.0 million, up 1.95% from the prior year.
• Total Non-Current Liabilities was $64.8 million for Q1 2026 at Abivax, down from $77.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $84.1 million in Q2 2024 to a low of $17.2 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $63.2 million across 5 years, with a median of $71.3 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities surged 151.96% in 2023, then declined 25.17% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $17.2 million in 2022, then soared by 151.96% to $43.4 million in 2023, then soared by 73.86% to $75.5 million in 2024, then increased by 1.95% to $77.0 million in 2025, then slipped by 15.85% to $64.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $64.8 million (Q1 2026), $77.0 million (Q4 2025), and $72.5 million (Q3 2025), per Business Quant data.